1.Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J: Cancer statistics in China, 2015. CA Cancer J Clin 2016, 66(2):115–132.
2.Siegel RL, Miller KD, Jemal A: Cancer statistics, 2016. CA Cancer J Clin 2016, 66(1):7–30.
3.Wirth M, Tammela T, Cicalese V, Gomez Veiga F, Delaere K, Miller K, Tubaro A, Schulze M, Debruyne F, Huland H et al: Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS). Eur Urol 2015, 67(3):482–491.
4.Sathiakumar N, Delzell E, Morrisey MA, Falkson C, Yong M, Chia V, Blackburn J, Arora T, Kilgore ML: Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006. Prostate Cancer Prostatic Dis 2011, 14(2):177–183.
5.Gdowski AS, Ranjan A, Vishwanatha JK: Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials. J Exp Clin Canc Res 2017, 36.
6.Pedersen EA, Shiozawa Y, Pienta KJ, Taichman RS: The prostate cancer bone marrow niche: more than just ‘fertile soil’. Asian J Androl 2012, 14(3):423–427.
7.Wan LL, Pantel K, Kang YB: Tumor metastasis: moving new biological insights into the clinic. Nat Med 2013, 19(11):1450–1464.
8.Weis SM, Cheresh DA: Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011, 17(11):1359–1370.
9.Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK: limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015, 43(7):e47.
10.Yu G, Wang LG, Han Y, He QY: clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 2012, 16(5):284–287.
11.Langfelder P, Horvath S: WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 2008, 9:559.
12.Hu ZJ, Chang YC, Wang Y, Huang CL, Liu Y, Tian F, Granger B, DeLisi C: VisANT 4.0: Integrative network platform to connect genes, drugs, diseases and therapies. Nucleic Acids Research 2013, 41(W1):W225-W231.
13.Langfelder P, Luo R, Oldham MC, Horvath S: Is my network module preserved and reproducible? PLoS Comput Biol 2011, 7(1):e1001057.
14.Penney KL, Schumacher FR, Kraft P, Mucci LA, Sesso HD, Ma J, Niu Y, Cheong JK, Hunter DJ, Stampfer MJ et al: Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels. Carcinogenesis 2011, 32(6):853–859.
15.Dunne PD, Dasgupta S, Blayney JK, McArt DG, Redmond KL, Weir JA, Bradley CA, Sasazuki T, Shirasawa S, Wang T et al: EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer. Clin Cancer Res 2016, 22(1):230–242.
16.Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, Habuka M, Tahmasebpoor S, Danielsson A, Edlund K et al: Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics 2014, 13(2):397–406.
17.Varambally S, Laxman B, Mehra R, Cao Q, Dhanasekaran SM, Tomlins SA, Granger J, Vellaichamy A, Sreekumar A, Yu J et al: Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. Neoplasia 2008, 10(11):1285–1294.
18.Zhang Z, Wu H, Zhou H, Gu Y, Bai Y, Yu S, An R, Qi J: Identification of potential key genes and high-frequency mutant genes in prostate cancer by using RNA-Seq data. Oncol Lett 2018, 15(4):4550–4556.
19.Gomes IM, Arinto P, Lopes C, Santos CR, Maia CJ: STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score. Urol Oncol 2014, 32(1):53 e23–59.
20.Uhlen M, Zhang C, Lee S, Sjostedt E, Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edfors F et al: A pathology atlas of the human cancer transcriptome. Science 2017, 357(6352).
21.Maresh EL, Mah V, Alavi M, Horvath S, Bagryanova L, Liebeskind ES, Knutzen LA, Zhou Y, Chia D, Liu AY et al: Differential expression of anterior gradient gene AGR2 in prostate cancer. BMC Cancer 2010, 10:680.
22.Xu F, Gao Y, Wang Y, Pan J, Sha J, Shao X, Kang X, Qin J, You MJ, Huang Y et al: Decreased TSPAN1 promotes prostate cancer progression and is a marker for early biochemical recurrence after radical prostatectomy. Oncotarget 2016, 7(39):63294–63305.
23.Consortium GT: The Genotype-Tissue Expression (GTEx) project. Nat Genet 2013, 45(6):580–585.
24.Edgar R, Mazor Y, Rinon A, Blumenthal J, Golan Y, Buzhor E, Livnat I, Ben-Ari S, Lieder I, Shitrit A et al: LifeMap Discovery: the embryonic development, stem cells, and regenerative medicine research portal. PLoS One 2013, 8(7):e66629.
25.Dankner M, Gray-Owen SD, Huang YH, Blumberg RS, Beauchemin N: CEACAM1 as a multi-purpose target for cancer immunotherapy. Oncoimmunology 2017, 6(7):e1328336.
26.Thies A, Moll I, Berger J, Wagener C, Brummer J, Schulze HJ, Brunner G, Schumacher U: CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol 2002, 20(10):2530–2536.
27.Windisch R, Pirschtat N, Kellner C, Chen-Wichmann L, Lausen J, Humpe A, Krause DS, Wichmann C: Oncogenic Deregulation of Cell Adhesion Molecules in Leukemia. Cancers 2019, 11(3).
28.Enarsson K, Lundin BS, Johnsson E, Brezicka T, Quiding-Jarbrink M: CD4(+)CD25(high) regulatory T cells reduce T cell transendothelial migration in cancer patients. Eur J Immunol 2007, 37(1):282–291.
29.Chatterjee S, Behnam Azad B, Nimmagadda S: The intricate role of CXCR4 in cancer. Adv Cancer Res 2014, 124:31–82.
30.Gautam J, Banskota S, Lee H, Lee YJ, Jeon YH, Kim JA, Jeong BS: Down-regulation of cathepsin S and matrix metalloproteinase–9 via Src, a non-receptor tyrosine kinase, suppresses triple-negative breast cancer growth and metastasis. Exp Mol Med 2018, 50.
31.Italiano D, Lena AM, Melino G, Candi E: Identification of NCF2/p67phox as a novel p53 target gene. Cell Cycle 2012, 11(24):4589–4596.
32.Lu X, Mu E, Wei Y, Riethdorf S, Yang QF, Yuan M, Yan J, Hua YL, Tiede BJ, Lu XM et al: VCAM–1 Promotes Osteolytic Expansion of Indolent Bone Micrometastasis of Breast Cancer by Engaging alpha 4 beta 1-Positive Osteoclast Progenitors. Cancer Cell 2011, 20(6):701–714.
33.Surdez D, Benetkiewicz M, Perrin V, Han ZY, Pierron G, Ballet S, Lamoureux F, Redini F, Decouvelaere AV, Daudigeos-Dubus E et al: Targeting the EWSR1-FLI1 Oncogene-Induced Protein Kinase PKC-beta Abolishes Ewing Sarcoma Growth. Cancer Res 2012, 72(17):4494–4503.
34.Lin SY, Pan HW, Liu SH, Jeng YM, Hu FC, Peng SY, Lai PL, Hsu HC: ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma. Clin Cancer Res 2008, 14(15):4814–4820.
35.Wang N, Zhan T, Ke T, Huang X, Ke D, Wang Q, Li H: Increased expression of RRM2 by human papillomavirus E7 oncoprotein promotes angiogenesis in cervical cancer. Brit J Cancer 2014, 110(4):1034–1044.
36.Chao CCK, Hung FC, Chao JJ: Gas7 Is Required for Mesenchymal Stem Cell-Derived Bone Development. Stem Cells Int 2013.
37.Hung FC, Chang YH, Sue LC, Chao CCK: Gas7 Mediates the Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells Into Functional Osteoblasts by Enhancing Runx2-Dependent Gene Expression. J Orthop Res 2011, 29(10):1528–1535.
38.Xie Y, Wang B: Downregulation of TNFAIP2 suppresses proliferation and metastasis in esophageal squamous cell carcinoma through activation of the Wnt/beta-catenin signaling pathway. Oncol Rep 2017, 37(5):2920–2928.
39.Zhuo YJ, Xi M, Wan YP, Hua W, Liu YL, Wan S, Zhou YL, Luo HW, Wu SL, Zhong WD et al: Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer. Int J Mol Med 2015, 35(4):966–972.
40.Jain M, Zhang LS, He M, Zhang YQ, Shen M, Kebebew E: TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma. Endocr-Relat Cancer 2013, 20(3):361–370.
41.Noll JE, Vandyke K, Hewett DR, Mrozik KM, Bala RJ, Williams SA, Kok CH, Zannettino ACW: PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma. J Hematol Oncol 2015, 8.